Related Experiment Videos
Microalbuminuria screening in the UK: are we meeting European standards?
1Department of Diabetes, Endocrinology, and Nutrition, University Hospital, Nottingham, UK.
Abstract:
European guidelines recommend annual screening for microalbuminuria in patients with Type 1 (insulin-dependent) diabetes mellitus (IDDM) of greater than 5 years' duration and in those with Type 2 (non-insulin-dependent) diabetes mellitus (NIDDM) from diagnosis. To determine the current provision of screening for microalbuminuria we performed a postal survey of all diabetologists in the United Kingdom. Of 556 questionnaires sent, 326 (59%) were returned (246 adult, 57 paediatric, 3 adolescent clinics) and of these 306 (55%) were suitable for analysis. Screening programmes have been established by 210 (69%) diabetologists: 70 of these in the last 2 years. 46 more plan to screen patients with IDDM within 2 years. 155 (92%) of 169 adult programmes perform annual screening in IDDM, 74% according to European guidelines (39% in NIDDM). Other clinics use age, type of diabetes or criteria such as blood pressure to target screening. An albumin/creatinine ratio (52%) on an early morning urine (56%) or random (29%) urine sample is most commonly requested. Financial constraint was the principal reason given in 32 (33%) of 96 clinics that do not currently screen. Other reasons included implementation of other developments with a higher priority (24%) and doubts about the medical value of screening (46%). Assuming respondents are representative of current UK practice, we conclude that microalbuminuria screening is available to patients in many clinics, but is neither universal nor always performed according to European guidelines.
Insights
Microalbuminuria screening for diabetes patients is available in many UK clinics, but not universally implemented per European guidelines. Financial constraints and differing priorities hinder wider adoption of this crucial diabetes complication screening.
Area of Science:
- Nephrology
- Endocrinology
- Public Health
Background:
- European guidelines advocate annual microalbuminuria screening for Type 1 (insulin-dependent) diabetes mellitus (IDDM) patients with >5 years duration and Type 2 (non-insulin-dependent) diabetes mellitus (NIDDM) from diagnosis.
- Microalbuminuria is an early indicator of diabetic kidney disease, necessitating effective screening protocols.
Purpose of the Study:
- To assess the current provision and adherence to European guidelines for microalbuminuria screening among diabetologists in the United Kingdom.
- To identify barriers to implementing universal microalbuminuria screening.
Main Methods:
- A postal survey was conducted among all diabetologists in the United Kingdom.
- 326 out of 556 questionnaires were returned, with 306 suitable for analysis, representing adult, pediatric, and adolescent diabetes clinics.
Main Results:
- 69% of surveyed diabetologists have established microalbuminuria screening programs, with 46% planning to implement them within two years.
- Annual screening in IDDM is performed by 92% of adult programs, but only 74% adhere to European guidelines (39% for NIDDM).
- Financial constraints (33%), higher priority developments (24%), and doubts about screening's medical value (46%) were cited as reasons for not screening.
Conclusions:
- Microalbuminuria screening is accessible to many UK diabetes patients, but its implementation is not universal and often deviates from European recommendations.
- Addressing financial barriers and clarifying the screening's clinical utility are essential for improving adherence to guidelines and patient outcomes.